The PREVAIL study is a phase 3 clinical trial investigating the effect of a drug called Obicetrapib in patients with Atherosclerotic Cardiovascular Disease (ASCVD). These patients are already on the highest possible doses of other lipid-lowering therapies but still need better control of their condition. This study is designed to see if Obicetrapib can further reduce the risk of serious heart-related events like heart attacks, strokes, and the need for emergency heart surgeries compared to a placebo.